Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.41 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8465127 | 1.00 | FAAH (0.56) | FAAHALDH1A1SMN1; SMN2SLC6A5MEN1 | |
| SCHEMBL21549707 | 0.94 | FAAH (0.51) | FAAHALDH1A1SMN1; SMN2SLC6A5MEN1 | |
| SCHEMBL30838580 | 0.87 | FAAH (0.69) | FAAHALDH1A1SMN1; SMN2SLC6A5MEN1 | |
| SCHEMBL30838577 | 0.87 | FAAH (0.69) | FAAHALDH1A1SMN1; SMN2SLC6A5MEN1 | |
| SCHEMBL9526860 | 0.87 | FAAH (0.69) | FAAHALDH1A1SMN1; SMN2SLC6A5MEN1 | |
| SCHEMBL30838579 | 0.87 | FAAH (0.69) | FAAHALDH1A1SMN1; SMN2SLC6A5MEN1 | |
| SCHEMBL15623807 | 0.87 | FAAH (0.69) | FAAHALDH1A1SMN1; SMN2SLC6A5MEN1 | |
| SCHEMBL9526869 | 0.87 | FAAH (0.69) | FAAHALDH1A1SMN1; SMN2SLC6A5MEN1 | |
| SCHEMBL9550539 | 0.85 | FAAH (0.66) | FAAHALDH1A1SMN1; SMN2SLC6A5MEN1 | |
| SCHEMBL15602675 | 0.85 | FAAH (0.66) | FAAHALDH1A1SMN1; SMN2SLC6A5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5981580-A | IN WHICH THE CARBOXY-TERMINUS HAS BEEN MODIFIED TO FORM VARIOUS AMIDES, ESTERS, KETONES, ALCOHOLS, ALCOHOL ESTERS AND NITRITES THEREOF, AND ARE USEFUL AS SUBSTRATES FOR N-MYRISTOYLTRANSFERASE (NMT) AND/OR ITS ACYL COENZYME | G. D. SEARLE & CO. (US) | 1999-11-09 | — | — | US | disclosed |
| WO-1999050229-A1 | FATTY ACID ANALOGS AND PRODRUGS | G.D. SEARLE & CO. (US) | 1999-10-07 | — | — | WO | disclosed |
| US-5952377-A | SUBSTRATES FOR N-MYRISTOYLTRANSFERASE (NMT) AND/OR ITS ACYL COENZYME, AS ANTI-VIRAL AND ANTI-FUNGAL AGENTS OR PRO-DRUGS; TREATING AIDS, LENTIVIRUSES SUCH AS THE HUMAN IMMUNODEFICIENCY VIRUS | G. D. SEARLE & CO. (US) | 1999-09-14 | — | — | US | disclosed |
| US-5929110-A | USEFUL AS SUBSTRATES FOR N-MYRISTOYLTRANSFERASE (NMT) AND/OR ITS ACYL COENZYME, AND AS ANTI-VIRAL AND ANTI-FUNGAL AGENTS OR PRO-DRUGS OF SUCH AGENTS | G. D. SEARLE & CO. (US) | 1999-07-27 | — | — | US | disclosed |
| US-5859052-A | TREATING LENTIVIRUS INFECTIONS, ESPECIALLY HUMAN IMMUNODEFICIENCY VIRUS | G. D. SEARLE & CO. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5744631-A | Fatty acid analogs and prodrugs | G.D. SEARLE & CO. (US) | 1998-04-28 | — | — | US | disclosed |
| US-5719290-A | METHYLOXYUNDECYL- OR DECYLOXYETHYL-NITRILE OR TETRAZOLE DERIVATIVES; VIRICIDES | G. D. SEARLE & CO. (US) | 1998-02-17 | — | — | US | disclosed |
| US-5672769-A | CHEMICAL INTERMEDIATES FOR VIRICIDES, FUNGICIDES | G. D. SEARLE & CO. (US) | 1997-09-30 | — | — | US | disclosed |
| US-5670650-A | ANTIVIRAL AND ANTIFUNGAL AGENTS | G. D. SEARLE & CO. (US) | 1997-09-23 | — | — | US | disclosed |
| US-5599947-A | VIRICIDES, FUNGICIDES OR THEIR PRODRUGS | G. D. SEARLE & CO. (US) | 1997-02-04 | — | — | US | disclosed |